Corticotropin-Releasing Hormone

PreclinicalSmall molecule

Corticotropin-Releasing Hormone is one of 51 small molecule programs targeting Cocaine Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cocaine DependenceActive, not recruiting

Cocaine DependencePreclinical

Active, not recruiting

Competition

Competitive Landscape

101 competitors in Cocaine Dependence

#DrugCompanyPhaseTrials

Permax

VValeant Pharmaceuticals

Phase 3

1 2

Bupropion XL

GSK

Phase 3

1 3

Celexa

AbbVie

Phase 2

3 4

Ritalin

Novartis

Phase 2

2 5

Buspar

Bristol-Myers Squibb

Phase 2

2 6

Tegretol

Novartis

Phase 2

2 7

Dostinex

Pfizer

Phase 2

2 8

Sabril

Lundbeck

Phase 2

2 9

Antabuse

Teva

Phase 2

1 10

Lioresal

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cocaine Dependence1 trial

Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence

Completed·CCentre for Addiction and Mental Health··NCT01984177·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Corticotropin-Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Corticotropin-Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Corticotropin-Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre for Addiction and Mental Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre for Addiction and Mental Health

Corticotropin-Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Dependence1 trial

References

Drug Info

Quick Facts

Related News